"Messy compromise" on combo SPCs in EU could increase thickets and litigation

This article was originally published in SRA

15 Jul 2011
News

Francesca Bruce @ScripFrancesca Francesca.bruce@informa.com

Executive Summary

More legal disputes between originators and generics companies could ensue if the Court of Justice of the European Union upholds the opinion¹ of one of its advocates general on whether companies can get supplementary protection certificates on their combination drugs, according to one legal expert familiar with the case.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS116333

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS116333

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

"Messy compromise" on combo SPCs in EU could increase thickets and litigation

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert